ST1-RTA IMMUNOTOXIN FOR UNRELATED DONOR BONE MARROW TRANSPLANTS

用于无关供体骨髓移植的 ​​ST1-RTA 免疫毒素

• 批准号: 3852368
• 负责人: JOSEPH ANTIN
• 金额: --
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3852368
• 关键词: CD5 molecule; T lymphocyte; bone marrow transplantation; clinical trials; disease /disorder prevention /control; drug screening /evaluation; graft versus host disease; homologous transplantation; human subject; human therapy evaluation; immunoconjugates; immunotherapy; monoclonal antibody; ricin

This is a Phase I/II trial of the use of a monoclonal F(ab')2 fragment conjugated to the A chain of ricin. The monoclonal antibody recognizes the CD5 cell surface protein. T cells that are CD5+ internalize the immunotoxin and are killed, thus reducing the number of infused T cells and reducing the risk of GvHD. We are assessing the therapy for rate of engraftment and rate of development of graft vs. host disease.

这是使用单克隆F（ab '）2片段 与蓖麻毒素的A链结合。单克隆抗体识别 CD5细胞表面蛋白。CD5+ T细胞内化免疫毒素 并被杀死，从而减少输注的T细胞的数量， GvHD的风险。我们正在评估植入率的治疗， 移植物抗宿主病的发展速度。